The ongoing debate over the pricing of Xtandi, a prostate cancer medication developed at the University of California, Los Angeles (UCLA) and marketed by Pfizer, has intensified with renewed calls for the federal government to intervene by permitting generic competition. This development coincides with Health and Human Services Secretary Robert F. Kennedy Jr.’s recent confirmation, bringing the issue to the forefront of national discourse.
Xtandi, known generically as enzalutamide, has been a focal point in discussions about drug affordability. Advocacy groups, including Knowledge Ecology International, have urged the Department of Health and Human Services (HHS) to exercise its authority to license patents for Xtandi to generic manufacturers. They argue that such action could significantly reduce the drug’s cost, which is notably higher in the United States compared to other high-income countries. ([news.bloomberglaw.com](https://news.bloomberglaw.com/ip-law/health-agency-pushed-to-license-cancer-drug-patents-to-cut-costs?utm_source=openai))
Historically, the National Institutes of Health (NIH) has received multiple petitions to invoke “march-in rights” under the Bayh-Dole Act, which would allow the government to license patents developed with federal funding to other manufacturers if the original product is not made available on reasonable terms. Despite these petitions, including those concerning Xtandi, the NIH has consistently declined to exercise these rights. ([hmpgloballearningnetwork.com](https://www.hmpgloballearningnetwork.com/site/frmc/blog/robert-f-kennedy-jrs-confirmation-and-unexpected-turn-drug-pricing-debate?utm_source=openai))
Secretary Kennedy’s stance on this issue is particularly noteworthy. During his confirmation hearings, he expressed openness to the idea of the government seizing drug patents to lower prices, a position that aligns with progressive policy proposals. This perspective suggests a potential shift in the administration’s approach to drug pricing and patent rights. ([statnews.com](https://www.statnews.com/pharmalot/2025/01/28/rfk-patents-pfizer-starboard-insulin-novo-obesity-veru-sage-biogen/?utm_source=openai))
Pfizer, the pharmaceutical company marketing Xtandi, has faced legal challenges regarding the drug’s patents. In August 2024, several generic manufacturers filed Abbreviated New Drug Applications (ANDAs) with the FDA, seeking approval to market generic versions of Xtandi. Pfizer responded by initiating patent infringement lawsuits against these companies in the U.S. District Court for the District of New Jersey, asserting the validity and infringement of its patents. ([sec.gov](https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/R25.htm?utm_source=openai))
As the debate continues, stakeholders from various sectors—including government agencies, pharmaceutical companies, advocacy groups, and the legal community—are closely monitoring the situation. The outcome of this dispute could have significant implications for drug pricing policies, patent law interpretations, and the accessibility of life-saving medications in the United States.